Devices, digital health, and the technology changing how care is delivered.
Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.
GSK is boosting its AI chops with a new deal worth up to $110 million with Relation.
Sanofi's new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.
Argon Medical is correcting affected convenience kits by removing included Spectra Medical Devices Lidocaine Ampules.
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
Doctronic acquired Summer Health to expand into pediatric care and strengthen its AI-powered primary care platform. The post Doctronic Acquires Summer Health to Expand into Pediatric Primary Care appeared first on MedCity News .
A survey of 112 health system executives finds that Epic’s hold on hospital IT keeps getting stronger — but startups still have a shot, provided they solve a specific problem, prove strong ROI or offer a product that Epic is lagging behind on. The post Epic-First Doesn’t Mean Epic-Only: Where Hospitals Are Still Buying from Startups appeared first on MedCity News .
Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.
After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the evidence.
High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
CMS’s new framework sounds like a gentle opt-in. There’s no requirement to meet every standard on day one, just a commitment to work toward doing the right thing. That sounds great. But to actually participate in the network, you have to meet a baseline level of interoperability. The post A New Era of Interoperability, But Who Gets Left Behind? appeared first on MedCity News .
The most common and most expensive misunderstanding in healthcare cloud strategy is treating the cloud as a destination you either reach or you do not, when it is really a progression through five distinct stages, each one unlocking capabilities the stage before it could not support. The post The Healthcare Cloud Maturity Model: The Five Stages Most Health Systems Skip appeared first on MedCity News .
A standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.
Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.
Novo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.
AbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.
Throne Science — a startup selling an AI-powered toilet camera that tracks gut health, hydration and urinary function — closed a $10 million Series A funding round. CEO Scott Hickle said the goal is to become a “smoke detector for colorectal cancer,” filling a monitoring gap he noted the wearables industry has largely ignored. The post Smart Toilet Sensor Startup Is Flush with $10M Funding appeared first on MedCity News .
The plan involves transferring production lines and cutting jobs, following a slowdown in two of the company’s key product lines.
The company recovered 186 million euros after it “largely completed the U.S. tariff refund process” in the quarter, CEO Roy Jakobs said on an earnings call.
Done well, NICU UM is so much more than an approval process. It is a clinical credibility engine that — when integrated with Case Management (CM) — drives every NICU admission toward the most appropriate, impactful care. The post Why Specialized UM Delivers on Every NICU Outcome appeared first on MedCity News .
A few minutes of interaction with a digital tablet and speaking can reveal patterns that once required advanced imaging, years of observation, or were just completely undetectable. The post Spotting Alzheimer’s Years Earlier Through AI and Clinically Meaningful Insights appeared first on MedCity News .
Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global biopharma companies on R&D productivity, market access and commercial performance.
Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.